2nd NovAliX Conference - Biophysics in Drug Discovery 2015

Confirmed Speakers

KEYNOTE LECTURE

Molecular Recognition in Protein-Ligand Complexes

Prof. Gerhard KLEBE
(PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany)

INVITED LECTURES

SESSION 1: Method Development & Emerging Technologies

No Crystal, No Problem: Hydrogen Deuterium Exchange Mass Spectrometry in Drug Discovery

Dr Nino CAMPOBASSO
(GLAXOSMITHKLINE, Collegeville, United States)

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Dr Pär NORDLUND
(KAROLINSKA INSTITUTE & NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore)

Second-Harmonic Generation (SHG) Measures and Resolves Protein Conformations: High-Throughput Structural Drug Discovery

Dr Joshua SALAFSKY
(BIODESY, South San Francisco, United States)

SESSION 2: Biophysics for Integral Membrane Proteins

Fluorine NMR Screening: Principles and Application to a Membrane Protein

Dr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

Improving the Biophysical Properties of GPCRs for Drug Screening and Structural Biology

Prof. Andreas PLÜCKTHUN
(UNIVERSITY OF ZÜRICH, Zurich, Switzerland)

SESSION 3: Impact of Biophysics on Drug Discovery Projects

Biophysical Approaches for Hit Finding and Evaluation at Bayer

Dr Ursula EGNER
(BAYER, Berlin, Germany)

Making Every Interaction Count: Impact of Biophysical Methods Across the AstraZeneca Small-Molecule Portfolio

2nd NovAliX Conference - Biophysics in Drug Discovery 2015

Confirmed Speakers

Dr Stefan GESCHWINDNER
(ASTRAZENECA, Mölndal, Sweden)

Some Examples of Biophysics Helping Drug Discovery

Prof. Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)

Biophysics and Structural Biology Enabling the Discovery of Therapeutic Solutions: from Small Molecule Inhibitors to Vaccine Design

Dr Vincent MIKOL
(SANOFI, Vitry-sur-Seine, France)

SESSION 4: The Use of Kinetics in Drug Discovery

CCR2 Antagonists: From Structure-Kinetics Relatiosnhips to in vivo Efficacy

Prof. Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

Towards a Better Understanding of the Structural Mechanisms of Kinase Inhibitor Binding Kinetics

Prof. Stefan KNAPP
(OXFORD UNIVERSITY, Oxford, United Kingdom)

Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure

Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)

SESSION 5: Special Focus on Epigenetics

When to get Biophysical with Readers, Writers and Erasers

Dr Chun-wa CHUNG
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics

Dr Robert A. COPELAND
(EPIZYME, Cambridge, United States)

Interrogating the Bromodomain Family Through Chemical Biology

2nd NovAliX Conference - Biophysics in Drug Discovery 2015

Confirmed Speakers

Dr Richard CUMMINGS
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

ORAL COMMUNICATIONS

Characterization of IL17A Inhibitors by Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS)

Mr Alfonso ESPADA
(ELI LILLY, ALCOBENDAS, Spain)

A Universal Homogeneous Assay for High-Throughput Determination of Binding Kinetics

Dr Amaury FERNANDEZ MONTALVAN
(BAYER, Biberach an der Riss, Germany)

Drug Discovery at the Single Molecule Level

Dr Anders GUNNARSSON
(ASTRAZENECA, Mölndal, Sweden)

First Crystal Structure of Transmembrane Domain of G-Protein-Coupled Receptor MGLU5 Provides Insight Into Efficient New Drugs Design

Dr Krzysztof OKRASA
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

CDK8 Inhibitors with Long Residence Time Emerging from a Retro-Design Approach: New Opportunities for Cancer Treatment

Dr Anita WEGERT
(MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

Strategies to Target Protein-Protein Interactions

Dr Marta WESTWOOD
(UCB, Slough, United Kingdom)